Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Clin Cancer Res. 2011 Aug 3;17(18):5945–5952. doi: 10.1158/1078-0432.CCR-11-0970

Figure 4.

Figure 4

HLA restriction of of VL peptide specific CTLs. (A) HLA class I but not HLA class II specific antibody or isotype control antibody (10 µg/ml) blocked the cytolysis of U266 tumor cells by U266 VL peptide-specific CTLs. (B) HLA class I but not HLA class II antibody or isotype control antibody (10 µg/ml) blocked the cytolysis of primary human CLL and PL tumor cells, respectively by VL peptide-specific CTLs. (C) U266 P21 peptide-specific CTLs specifically lysed HLA-A*0201+ primary FL cells that shared the P21 epitope: Tumor (FL4, P21+), but not the same patients’ PBMC: PBMC(FL4) or HLA-A*0201 tumor cells that did not express P21(FL5,P21−).